Literature DB >> 25210418

Schizophrenia therapy options increasing.

Kunj Gohil, Brielle Carramusa.   

Abstract

New medications may soon offer more effective treatments for the approximately 2.5 million patients globally with schizophrenia. Current therapies in 2012 yielded $5.2 billion in global market sales, but by 2022 that is expected to reach $7.9 billion.

Entities:  

Year:  2014        PMID： 25210418      PMCID： PMC4159058     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  3 in total

Review 1.  Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains.

Authors:  Leslie Citrome
Journal:  J Clin Psychiatry       Date:  2014       Impact factor: 4.384

Review 2.  The pipeline and future of drug development in schizophrenia.

Authors:  J A Gray; B L Roth
Journal:  Mol Psychiatry       Date:  2007-07-31       Impact factor: 13.437

Review 3.  Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia.

Authors:  Gabriel Kaplan; Julio Casoy; Jacqueline Zummo
Journal:  Patient Prefer Adherence       Date:  2013-11-13       Impact factor: 2.711
  3 in total
  1 in total

Review 1.  Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy.

Authors:  Fernanda S Tonin; Astrid Wiens; Fernando Fernandez-Llimos; Roberto Pontarolo
Journal:  Core Evid       Date:  2016-12-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.